A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)

Prior treatment

• Exacerbation of underlying lung disease requiring change in therapy or hospitalization within 28 days prior to randomization
• Receiving \>10 L/min oxygen supplementation by any mode of delivery at rest
• Initiation of pulmonary rehabilitation or ongoing acute phase of rehabilitation within 28 days prior to randomization.
• Receipt of investigational or interventional therapy within 42 days OR 5 half-lives (whichever is longer) prior to randomization.

Other illness

• Diagnosis of PH Group 1 (eg, pulmonary arterial hypertension), Group 2 (related to left heart disease), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).
• History of intolerance to mosliciguat, or sGC stimulators or activators.

• Participants willing and able to provide informed consent.
• Participants with diagnosis of pulmonary hypertension (PH) associated with interstitial lung disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed disease include:
  • Idiopathic interstitial pneumonia (IIP)
  • Chronic Hypersensitivity pneumonitis
  • ILD associated connective tissue disease (CTD)
• Confirmed pulmonary hypertension by right heart catheterization (RHC).
• Ability to perform 6-minute walk distance ≥100 meters.